Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an “intriguing potential blockbuster,” with its GLP-1/GIP dual agonist mechanism that could allow for superior efficacy relative to obesity treatment available options, the analyst tells investors in a research note. However, Citi says investors need to learn more regarding VK2735’s profile – in particular, safety data from larger and longer trials given that high discontinuations are already a challenge in the market. Furthermore, considering the substantial investment made by big pharma, the obesity market is highly capital intensive, a great challenge for emerging players, contends the firm. Such challenges, along with Viking’s “long timelines with modest news flow,” keep Citi on the sidelines for now.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Reports Strong Trials and Financial Health
- Viking Therapeutics price target raised to $125 from $122 at Raymond James
- Viking Therapeutics Reports Positive 2024 Financials and Clinical Progress
- Closing Bell Movers: Semis down sharply after results
- Viking Therapeutics reports Q4 EPS (32c), consensus (27c)